Tvardi Therapeutics (NASDAQ:TVRD) Cut to Market Perform at Raymond James Financial

Raymond James Financial lowered shares of Tvardi Therapeutics (NASDAQ:TVRD) from an outperform rating to a market perform rating in a research report released on Tuesday morning, MarketBeat.com reports.

Several other brokerages have also recently weighed in on TVRD. Barclays set a $5.00 target price on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Saturday, September 27th. Cantor Fitzgerald cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday. BTIG Research reduced their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a report on Monday. Finally, Piper Sandler cut shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Down 2.4%

NASDAQ TVRD opened at $6.48 on Tuesday. The company has a 50 day simple moving average of $30.57. Tvardi Therapeutics has a one year low of $5.65 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $43,000. Headlands Technologies LLC acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $80,000. New York State Common Retirement Fund acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $92,000. Finally, Bank of America Corp DE acquired a new stake in Tvardi Therapeutics during the second quarter worth approximately $399,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.